Ezra Cohen to Head and Neck Neoplasms
This is a "connection" page, showing publications Ezra Cohen has written about Head and Neck Neoplasms.
Connection Strength
19.247
-
Method for estimation of apoptotic cell fraction of cytotherapy using in vivo fluorine-19 magnetic resonance: pilot study in a patient with head and neck carcinoma receiving tumor-infiltrating lymphocytes labeled with perfluorocarbon nanoemulsion. J Immunother Cancer. 2023 06; 11(6).
Score: 0.530
-
Intralesional SD-101 in Combination with Pembrolizumab in Anti-PD-1 Treatment-Naïve Head and Neck Squamous Cell Carcinoma: Results from a Multicenter, Phase II Trial. Clin Cancer Res. 2022 03 15; 28(6):1157-1166.
Score: 0.488
-
Xevinapant or placebo plus chemoradiotherapy in locally advanced squamous cell carcinoma of the head and neck: TrilynX phase III study design. Future Oncol. 2022 May; 18(14):1669-1678.
Score: 0.485
-
Hereditary oral squamous cell carcinoma associated with CDKN2A germline mutation: a case report. J Otolaryngol Head Neck Surg. 2022 Feb 05; 51(1):5.
Score: 0.484
-
Inevitable Progress-Relying on the Immune System, Not Chance. Clin Cancer Res. 2022 02 01; 28(3):435-437.
Score: 0.478
-
The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of squamous cell carcinoma of the head and neck (HNSCC). J Immunother Cancer. 2019 07 15; 7(1):184.
Score: 0.405
-
Pembrolizumab versus methotrexate, docetaxel, or cetuximab for recurrent or metastatic head-and-neck squamous cell carcinoma (KEYNOTE-040): a randomised, open-label, phase 3 study. Lancet. 2019 01 12; 393(10167):156-167.
Score: 0.388
-
Biomarkers predict enhanced clinical outcomes with afatinib versus methotrexate in patients with second-line recurrent and/or metastatic head and neck cancer. Ann Oncol. 2017 Oct 01; 28(10):2526-2532.
Score: 0.358
-
Serum antibodies open the door to prediction and prognostication in human papillomavirus-related head and neck cancer. Cancer. 2017 11 15; 123(22):4310-4313.
Score: 0.358
-
Combination immunotherapy with TLR agonists and checkpoint inhibitors suppresses head and neck cancer. JCI Insight. 2017 09 21; 2(18).
Score: 0.357
-
American Cancer Society Head and Neck Cancer Survivorship Care Guideline. CA Cancer J Clin. 2016 05; 66(3):203-39.
Score: 0.322
-
Current Treatment Options for Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma. J Clin Oncol. 2015 Oct 10; 33(29):3305-13.
Score: 0.310
-
Ex vivo antibody-dependent cellular cytotoxicity inducibility predicts efficacy of cetuximab. Cancer Immunol Res. 2015 May; 3(5):567-74.
Score: 0.300
-
Mechanisms of and therapeutic approaches for overcoming resistance to epidermal growth factor receptor (EGFR)-targeted therapy in squamous cell carcinoma of the head and neck (SCCHN). Oral Oncol. 2015 May; 51(5):399-408.
Score: 0.299
-
Reply to s. Chakraborty et al. J Clin Oncol. 2015 Mar 10; 33(8):968.
Score: 0.298
-
Afatinib efficacy against squamous cell carcinoma of the head and neck cell lines in vitro and in vivo. Target Oncol. 2015 Dec; 10(4):501-8.
Score: 0.296
-
Towards a personalized treatment of head and neck cancer. Am Soc Clin Oncol Educ Book. 2015; 28-32.
Score: 0.296
-
Targeting the PI3K/AKT/mTOR pathway in squamous cell carcinoma of the head and neck. Oral Oncol. 2015 Apr; 51(4):291-8.
Score: 0.295
-
Afatinib versus placebo as adjuvant therapy after chemoradiation in a double-blind, phase III study (LUX-Head & Neck 2) in patients with primary unresected, clinically intermediate-to-high-risk head and neck cancer: study protocol for a randomized controlled trial. Trials. 2014 Nov 29; 15:469.
Score: 0.294
-
Phase III randomized trial of induction chemotherapy in patients with N2 or N3 locally advanced head and neck cancer. J Clin Oncol. 2014 Sep 01; 32(25):2735-43.
Score: 0.287
-
Open Access in biomedical sciences: what the current turning point means more specifically to Oral Oncology contributors and readers. Oral Oncol. 2013 Oct; 49(10):985-6.
Score: 0.271
-
Pharmacoeconomic issues in head and neck oncology. Curr Opin Oncol. 2013 May; 25(3):213-7.
Score: 0.264
-
Multidisciplinary care of the patient with head and neck cancer. Surg Oncol Clin N Am. 2013 Apr; 22(2):179-215.
Score: 0.259
-
Molecular phenotype predicts sensitivity of squamous cell carcinoma of the head and neck to epidermal growth factor receptor inhibition. Mol Oncol. 2013 Jun; 7(3):359-68.
Score: 0.255
-
Phase II study of gefitinib adaptive dose escalation to skin toxicity in recurrent or metastatic squamous cell carcinoma of the head and neck. Oral Oncol. 2012 Sep; 48(9):887-92.
Score: 0.245
-
Quality of life scores as prognostic factors of overall survival in advanced head and neck cancer: analysis of a phase III randomized trial of pemetrexed plus cisplatin versus cisplatin monotherapy. Oral Oncol. 2012 Aug; 48(8):723-9.
Score: 0.244
-
Current treatment options for metastatic head and neck cancer. Curr Treat Options Oncol. 2012 Mar; 13(1):35-46.
Score: 0.243
-
A phase II study of lapatinib in recurrent/metastatic squamous cell carcinoma of the head and neck. Clin Cancer Res. 2012 Apr 15; 18(8):2336-43.
Score: 0.243
-
Novel targeted therapies in head and neck cancer. Expert Opin Investig Drugs. 2012 Mar; 21(3):281-95.
Score: 0.241
-
Role of molecular markers in the management of head and neck cancers. Curr Opin Oncol. 2011 May; 23(3):259-64.
Score: 0.229
-
Effect of complementary pathway blockade on efficacy of combination enzastaurin and rapamycin. Head Neck. 2011 Dec; 33(12):1774-82.
Score: 0.228
-
Phase II trial of pemetrexed-based induction chemotherapy followed by concomitant chemoradiotherapy in previously irradiated patients with squamous cell carcinoma of the head and neck. Ann Oncol. 2011 Nov; 22(11):2501-2507.
Score: 0.227
-
[18F]Fluorodeoxyglucose positron emission tomography in the initial staging of squamous cell carcinoma of the head and neck: promise, evidence, and reality. J Clin Oncol. 2010 Oct 01; 28(28):e516; author reply e517.
Score: 0.217
-
Epidermal growth factor receptor inhibitor gefitinib added to chemoradiotherapy in locally advanced head and neck cancer. J Clin Oncol. 2010 Jul 10; 28(20):3336-43.
Score: 0.215
-
Personalizing cancer care: updates on head and neck cancer. Expert Rev Anticancer Ther. 2009 Sep; 9(9):1219-22.
Score: 0.205
-
Phase II study of sunitinib malate in head and neck squamous cell carcinoma. Invest New Drugs. 2010 Oct; 28(5):677-83.
Score: 0.203
-
Mechanisms of resistance to EGFR inhibitors in head and neck cancer. Head Neck. 2009 Aug; 31(8):1086-94.
Score: 0.203
-
Factors associated with clinical benefit from epidermal growth factor receptor inhibitors in recurrent and metastatic squamous cell carcinoma of the head and neck. Oral Oncol. 2009 Oct; 45(10):e155-60.
Score: 0.202
-
Surrogate endpoints in head and neck cancer. Lancet Oncol. 2009 Apr; 10(4):309-10.
Score: 0.199
-
Erlotinib and bevacizumab in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck: a phase I/II study. Lancet Oncol. 2009 Mar; 10(3):247-57.
Score: 0.197
-
A feed-forward loop involving protein kinase Calpha and microRNAs regulates tumor cell cycle. Cancer Res. 2009 Jan 01; 69(1):65-74.
Score: 0.195
-
Targeting angiogenesis in head and neck cancer. Semin Oncol. 2008 Jun; 35(3):274-85.
Score: 0.188
-
Treatment of squamous cell carcinoma of the head and neck in the metastatic and refractory settings: advances in chemotherapy and the emergence of small molecule epidermal growth factor receptor kinase inhibitors. Curr Cancer Drug Targets. 2007 Nov; 7(7):666-73.
Score: 0.180
-
A disturbance in the force--mitochondrial mutations in squamous cell carcinoma of the head and neck. Clin Cancer Res. 2007 Aug 01; 13(15 Pt 1):4317-9.
Score: 0.177
-
Phase I trial of tirapazamine, cisplatin, and concurrent accelerated boost reirradiation in patients with recurrent head and neck cancer. Int J Radiat Oncol Biol Phys. 2007 Mar 01; 67(3):678-84.
Score: 0.172
-
High survival and organ function rates after primary chemoradiotherapy for intermediate-stage squamous cell carcinoma of the head and neck treated in a multicenter phase II trial. J Clin Oncol. 2006 Jul 20; 24(21):3438-44.
Score: 0.165
-
Protein kinase C zeta mediates epidermal growth factor-induced growth of head and neck tumor cells by regulating mitogen-activated protein kinase. Cancer Res. 2006 Jun 15; 66(12):6296-303.
Score: 0.164
-
Role of epidermal growth factor receptor pathway-targeted therapy in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck. J Clin Oncol. 2006 Jun 10; 24(17):2659-65.
Score: 0.164
-
Phase II trial of gefitinib 250 mg daily in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck. Clin Cancer Res. 2005 Dec 01; 11(23):8418-24.
Score: 0.158
-
Response of some head and neck cancers to epidermal growth factor receptor tyrosine kinase inhibitors may be linked to mutation of ERBB2 rather than EGFR. Clin Cancer Res. 2005 Nov 15; 11(22):8105-8.
Score: 0.157
-
Epidermal growth factor receptor directed therapy in head and neck cancer. Crit Rev Oncol Hematol. 2006 Jan; 57(1):25-43.
Score: 0.156
-
State-of-the-art management of locally advanced head and neck cancer. Br J Cancer. 2005 Apr 25; 92(8):1341-8.
Score: 0.151
-
Novel therapeutic targets in squamous cell carcinoma of the head and neck. Semin Oncol. 2004 Dec; 31(6):755-68.
Score: 0.147
-
The expanding role of systemic therapy in head and neck cancer. J Clin Oncol. 2004 May 01; 22(9):1743-52.
Score: 0.141
-
Phase II trial of ZD1839 in recurrent or metastatic squamous cell carcinoma of the head and neck. J Clin Oncol. 2003 May 15; 21(10):1980-7.
Score: 0.132
-
A Randomized Multi-institutional Phase II Trial of Everolimus as Adjuvant Therapy in Patients with Locally Advanced Squamous Cell Cancer of the Head and Neck. Clin Cancer Res. 2022 12 01; 28(23):5040-5048.
Score: 0.128
-
Somatic 9p24.1 alterations in HPV- head and neck squamous cancer dictate immune microenvironment and anti-PD-1 checkpoint inhibitor activity. Proc Natl Acad Sci U S A. 2022 11 22; 119(47):e2213835119.
Score: 0.128
-
A phase I study of avelumab, palbociclib, and cetuximab in patients with recurrent or metastatic head and neck squamous cell carcinoma. Oral Oncol. 2022 12; 135:106219.
Score: 0.127
-
Safety and Efficacy of Pembrolizumab in Combination with Acalabrutinib in Advanced Head and Neck Squamous Cell Carcinoma: Phase 2 Proof-of-Concept Study. Clin Cancer Res. 2022 Mar 01; 28(5):903-914.
Score: 0.122
-
Patient selection for immunotherapy in head and neck cancer - Authors' reply. Lancet Oncol. 2021 07; 22(7):e291-e292.
Score: 0.116
-
Disruption of the HER3-PI3K-mTOR oncogenic signaling axis and PD-1 blockade as a multimodal precision immunotherapy in head and neck cancer. Nat Commun. 2021 04 22; 12(1):2383.
Score: 0.115
-
Meta-analysis of chemotherapy in head and neck cancer (MACH-NC): An update on 107 randomized trials and 19,805 patients, on behalf of MACH-NC Group. Radiother Oncol. 2021 03; 156:281-293.
Score: 0.113
-
Comparing programmed death ligand 1 scores for predicting pembrolizumab efficacy in head and neck cancer. Mod Pathol. 2021 03; 34(3):532-541.
Score: 0.111
-
Cost-effectiveness analysis of nivolumab for the treatment of squamous cell carcinoma of the head and neck in the United States. J Med Econ. 2020 May; 23(5):442-447.
Score: 0.105
-
HPV16 E5 Mediates Resistance to PD-L1 Blockade and Can Be Targeted with Rimantadine in Head and Neck Cancer. Cancer Res. 2020 02 15; 80(4):732-746.
Score: 0.104
-
Afatinib versus methotrexate as second-line treatment in Asian patients with recurrent or metastatic squamous cell carcinoma of the head and neck progressing on or after platinum-based therapy (LUX-Head & Neck 3): an open-label, randomised phase III trial. Ann Oncol. 2019 11 01; 30(11):1831-1839.
Score: 0.103
-
Selection of Head and Neck Cancer Patients for Intensive Therapy. Int J Radiat Oncol Biol Phys. 2020 01 01; 106(1):157-166.
Score: 0.103
-
Afatinib as second-line treatment in patients with recurrent/metastatic squamous cell carcinoma of the head and neck: Subgroup analyses of treatment adherence, safety and mode of afatinib administration in the LUX-Head and Neck 1 trial. Oral Oncol. 2019 10; 97:82-91.
Score: 0.102
-
Immune Modulation of Head and Neck Squamous Cell Carcinoma and the Tumor Microenvironment by Conventional Therapeutics. Clin Cancer Res. 2019 07 15; 25(14):4211-4223.
Score: 0.099
-
Randomized phase II trial of cixutumumab alone or with cetuximab for refractory recurrent/metastatic head and neck squamous cell carcinoma. Oral Oncol. 2018 07; 82:83-90.
Score: 0.094
-
Induction chemotherapy in locally advanced squamous cell carcinoma of the head and neck: role, controversy, and future directions. Ann Oncol. 2018 05 01; 29(5):1130-1140.
Score: 0.093
-
A phase I open-label dose-escalation study of the anti-HER3 monoclonal antibody LJM716 in patients with advanced squamous cell carcinoma of the esophagus or head and neck and HER2-overexpressing breast or gastric cancer. BMC Cancer. 2017 Sep 12; 17(1):646.
Score: 0.089
-
Role of Induction Chemotherapy Prior to Chemoradiation in Head and Neck Squamous Cell Cancer-Systematic Review and Meta-analysis. Cancer J. 2017 Mar/Apr; 23(2):79-83.
Score: 0.086
-
Immunotherapy of head and neck cancer: Emerging clinical trials from a National Cancer Institute Head and Neck Cancer Steering Committee Planning Meeting. Cancer. 2017 Apr 01; 123(7):1259-1271.
Score: 0.085
-
Final Results of a Randomized Phase 2 Trial Investigating the Addition of Cetuximab to Induction Chemotherapy and Accelerated or Hyperfractionated Chemoradiation for Locoregionally Advanced Head and Neck Cancer. Int J Radiat Oncol Biol Phys. 2016 09 01; 96(1):21-9.
Score: 0.081
-
Considering the survivorship care needs of head and neck cancer survivors. Oral Oncol. 2016 06; 57:61-2.
Score: 0.081
-
Afatinib versus methotrexate in older patients with second-line recurrent and/or metastatic head and neck squamous cell carcinoma: subgroup analysis of the LUX-Head & Neck 1 trial. Ann Oncol. 2016 08; 27(8):1585-93.
Score: 0.081
-
A Novel Peptide for Simultaneously Enhanced Treatment of Head and Neck Cancer and Mitigation of Oral Mucositis. PLoS One. 2016; 11(4):e0152995.
Score: 0.081
-
Response-adapted volume de-escalation (RAVD) in locally advanced head and neck cancer. Ann Oncol. 2016 05; 27(5):908-13.
Score: 0.080
-
Importance of Radiation Oncologist Experience Among Patients With Head-and-Neck Cancer Treated With Intensity-Modulated Radiation Therapy. J Clin Oncol. 2016 Mar 01; 34(7):684-90.
Score: 0.079
-
Afatinib versus methotrexate as second-line treatment in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck progressing on or after platinum-based therapy (LUX-Head & Neck 1): an open-label, randomised phase 3 trial. Lancet Oncol. 2015 May; 16(5):583-94.
Score: 0.075
-
Combined TP53 mutation/3p loss correlates with decreased radiosensitivity and increased matrix-metalloproteinase activity in head and neck carcinoma. Oral Oncol. 2015 May; 51(5):470-5.
Score: 0.075
-
Aspiration pneumonia after concurrent chemoradiotherapy for head and neck cancer. Cancer. 2015 Apr 15; 121(8):1303-11.
Score: 0.074
-
Integrative analysis of head and neck cancer identifies two biologically distinct HPV and three non-HPV subtypes. Clin Cancer Res. 2015 Feb 15; 21(4):870-81.
Score: 0.074
-
Comparison of outcomes of locoregionally advanced oropharyngeal and non-oropharyngeal squamous cell carcinoma over two decades. Ann Oncol. 2015 Jan; 26(1):198-205.
Score: 0.073
-
Rare occurrence of EGFRvIII deletion in head and neck squamous cell carcinoma. Oral Oncol. 2015 Jan; 51(1):53-8.
Score: 0.073
-
Multi-tiered genomic analysis of head and neck cancer ties TP53 mutation to 3p loss. Nat Genet. 2014 Sep; 46(9):939-43.
Score: 0.072
-
Integrative and comparative genomic analysis of HPV-positive and HPV-negative head and neck squamous cell carcinomas. Clin Cancer Res. 2015 Feb 01; 21(3):632-41.
Score: 0.072
-
DNA repair biomarkers XPF and phospho-MAPKAP kinase 2 correlate with clinical outcome in advanced head and neck cancer. PLoS One. 2014; 9(7):e102112.
Score: 0.072
-
Rationale and design of LUX-Head & Neck 1: a randomised, Phase III trial of afatinib versus methotrexate in patients with recurrent and/or metastatic head and neck squamous cell carcinoma who progressed after platinum-based therapy. BMC Cancer. 2014 Jun 28; 14:473.
Score: 0.071
-
A randomized, phase II study of afatinib versus cetuximab in metastatic or recurrent squamous cell carcinoma of the head and neck. Ann Oncol. 2014 Sep; 25(9):1813-1820.
Score: 0.071
-
An open-label single-arm, phase II trial of zalutumumab, a human monoclonal anti-EGFR antibody, in patients with platinum-refractory squamous cell carcinoma of the head and neck. Cancer Chemother Pharmacol. 2014 Jun; 73(6):1227-39.
Score: 0.070
-
Race and competing mortality in advanced head and neck cancer. Oral Oncol. 2014 Jan; 50(1):40-4.
Score: 0.068
-
Modifiable risk behaviors in patients with head and neck cancer. Cancer. 2013 Jul 01; 119(13):2419-26.
Score: 0.066
-
A phase I dose escalation study of Ad GV.EGR.TNF.11D (TNFerade™ Biologic) with concurrent chemoradiotherapy in patients with recurrent head and neck cancer undergoing reirradiation. Ann Oncol. 2013 Mar; 24(3):769-76.
Score: 0.064
-
The future of induction chemotherapy for head and neck squamous cell carcinoma. Oral Oncol. 2012 Nov; 48(11):1065-7.
Score: 0.063
-
The role of chemotherapy in locally advanced head and neck squamous cell carcinoma. Semin Radiat Oncol. 2012 Jul; 22(3):198-206.
Score: 0.062
-
Single sample expression-anchored mechanisms predict survival in head and neck cancer. PLoS Comput Biol. 2012 Jan; 8(1):e1002350.
Score: 0.060
-
Prior chemoradiotherapy adversely impacts outcomes of recurrent and second primary head and neck cancer treated with concurrent chemotherapy and reirradiation. Cancer. 2011 Oct 15; 117(20):4671-8.
Score: 0.058
-
Airway management before chemoradiation for advanced head and neck cancer. Head Neck. 2012 Feb; 34(2):254-9.
Score: 0.057
-
A randomized phase II study of 5-fluorouracil, hydroxyurea, and twice-daily radiotherapy compared with bevacizumab plus 5-fluorouracil, hydroxyurea, and twice-daily radiotherapy for intermediate-stage and T4N0-1 head and neck cancers. Ann Oncol. 2011 Oct; 22(10):2304-9.
Score: 0.057
-
Germline polymorphisms discovered via a cell-based, genome-wide approach predict platinum response in head and neck cancers. Transl Res. 2011 May; 157(5):265-72.
Score: 0.056
-
Factors associated with long-term speech and swallowing outcomes after chemoradiotherapy for locoregionally advanced head and neck cancer. Arch Otolaryngol Head Neck Surg. 2010 Dec; 136(12):1226-34.
Score: 0.056
-
Adjuvant chemotherapy prior to postoperative concurrent chemoradiotherapy for locoregionally advanced head and neck cancer. Radiother Oncol. 2010 Nov; 97(2):318-21.
Score: 0.055
-
Efficacy of the multi-kinase inhibitor enzastaurin is dependent on cellular signaling context. Mol Cancer Ther. 2010 Oct; 9(10):2814-24.
Score: 0.055
-
New strategies in head and neck cancer: understanding resistance to epidermal growth factor receptor inhibitors. Clin Cancer Res. 2010 May 01; 16(9):2489-95.
Score: 0.053
-
Detection of tumor epidermal growth factor receptor pathway dependence by serum mass spectrometry in cancer patients. Cancer Epidemiol Biomarkers Prev. 2010 Feb; 19(2):358-65.
Score: 0.053
-
Predictors of competing mortality in advanced head and neck cancer. J Clin Oncol. 2010 Jan 01; 28(1):15-20.
Score: 0.052
-
The MET receptor tyrosine kinase is a potential novel therapeutic target for head and neck squamous cell carcinoma. Cancer Res. 2009 Apr 01; 69(7):3021-31.
Score: 0.050
-
Phase III study of gefitinib compared with intravenous methotrexate for recurrent squamous cell carcinoma of the head and neck [corrected]. J Clin Oncol. 2009 Apr 10; 27(11):1864-71.
Score: 0.050
-
Design of Phase II cancer trials for evaluation of cytostatic/cytotoxic agents. J Biopharm Stat. 2009; 19(3):524-9.
Score: 0.049
-
Characteristics associated with swallowing changes after concurrent chemotherapy and radiotherapy in patients with head and neck cancer. Arch Otolaryngol Head Neck Surg. 2008 Oct; 134(10):1060-5.
Score: 0.048
-
Free-flap reconstruction in the doubly irradiated patient population. Plast Reconstr Surg. 2008 Jul; 122(1):125-132.
Score: 0.047
-
Induction chemotherapy and concurrent chemoradiotherapy for locoregionally advanced head and neck cancer: a multi-institutional phase II trial investigating three radiotherapy dose levels. Ann Oncol. 2008 Oct; 19(10):1787-94.
Score: 0.047
-
Introduction: head and neck cancer. Semin Oncol. 2008 Jun; 35(3):196-7.
Score: 0.047
-
Phase I study of bevacizumab added to fluorouracil- and hydroxyurea-based concomitant chemoradiotherapy for poor-prognosis head and neck cancer. J Clin Oncol. 2008 Apr 01; 26(10):1732-41.
Score: 0.046
-
A randomized validation study comparing embedded versus extracted FACT Head and Neck Symptom Index scores. Qual Life Res. 2007 Dec; 16(10):1615-26.
Score: 0.045
-
A phase I trial of docetaxel based induction and concomitant chemotherapy in patients with locally advanced head and neck cancer. Cancer Invest. 2007 Sep; 25(6):435-44.
Score: 0.045
-
A phase II trial of perifosine, an oral alkylphospholipid, in recurrent or metastatic head and neck cancer. Cancer Biol Ther. 2006 Jul; 5(7):766-70.
Score: 0.041
-
Planned post-chemoradiation neck dissection: significance of radiation dose. Laryngoscope. 2006 Jan; 116(1):33-6.
Score: 0.040
-
A genome-wide screen for microdeletions reveals disruption of polarity complex genes in diverse human cancers. Cancer Res. 2010 Mar 15; 70(6):2158-64.
Score: 0.013